We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.86%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$6.46B
AUM Growth
+$1.05B
Cap. Flow
-$262M
Cap. Flow %
-4.05%
Top 10 Hldgs %
39.98%
Holding
155
New
25
Increased
25
Reduced
25
Closed
31

Top Buys

Rank Stock Value
1
ALEC icon
Alector
ALEC
+$249M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$112M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$71.9M
4
ENDP
Endo International plc
ENDP
+$58M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$53M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$259M
2
BIIB icon
Biogen
BIIB
+$235M
3
AGN
Allergan plc
AGN
+$128M
4
CVS icon
CVS Health
CVS
+$52M
5
CNC icon
Centene
CNC
+$48.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.6%
2 Miscellaneous 1.26%
3 Financials 1.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALLK
126
DELISTED
Allakos
ALLK
– –
-175,000
Closed -$9.15M
BLUE
127
DELISTED
bluebird bio
BLUE
– –
-29,892
Closed -$38.4M
BSX icon
128
CALL
Boston Scientific
BSX
$63.8B
– –
-250,000
Closed -$8.84M
CNC icon
129
Centene
CNC
$33.5B
– –
-834,800
Closed -$48.1M
CVS icon
130
CVS Health
CVS
$121B
– –
-793,800
Closed -$52M
DVA icon
131
DaVita
DVA
$12.2B
– –
-534,000
Closed -$27.5M
ECOR icon
132
electroCore
ECOR
$88.3M
– –
-26,548
Closed -$2.49M
HCA icon
133
HCA Healthcare
HCA
$91.9B
– –
-75,900
Closed -$9.45M
IRWD icon
134
Ironwood Pharmaceuticals
IRWD
$669M
– –
-3,436,332
Closed -$29.8M
MOH icon
135
Molina Healthcare
MOH
$10.9B
– –
-305,000
Closed -$35.4M
PFE icon
136
Pfizer
PFE
$157B
– –
-634,719
Closed -$26.3M
RDHL
137
Redhill Biopharma
RDHL
$3.52M
– –
-55
Closed -$303K
SAGE
138
DELISTED
Sage Therapeutics
SAGE
– –
-36,300
Closed -$3.48M
THC icon
139
Tenet Healthcare
THC
$21B
– –
-562,785
Closed -$9.65M
UNH icon
140
UnitedHealth
UNH
$340B
– –
-186,500
Closed -$46.5M
VTAK icon
141
Catheter Precision
VTAK
$552K
– –
-1
Closed -$2.78M
YI
142
111 Inc
YI
$29.9M
– –
-50,000
Closed -$3.07M
ALIM
143
DELISTED
Alimera Sciences
ALIM
– –
-16,667
Closed -$180K
ICPT
144
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-66,000
Closed -$6.65M
ICPT
145
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-47,800
Closed -$4.82M
SPPI
146
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-2,265,500
Closed -$19.8M
ADMS
147
CALL
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-100,000
Closed -$854K
IMMU
148
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-100,000
Closed -$1.43M
AGN
149
DELISTED
Allergan plc
AGN
– –
-957,000
Closed -$128M
DERM
150
DELISTED
Dermira, Inc.
DERM
– –
-1,031,596
Closed -$7.42M
3 4 5
6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2019 Portfolio in Review

As of Q1 2019, OrbiMed held 155 positions worth $6.46B, up 19% from $5.41B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $262M in Q1 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $128M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in Alector worth $247M.

  • OrbiMed's largest Q1 2019 buy was Alector: 13,182,329 shares worth $247M.
  • OrbiMed added most to Neurocrine Biosciences in Q1 2019, an estimated $112M increase.
  • OrbiMed's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $259M.
  • OrbiMed fully exited Allergan plc in Q1 2019, selling an estimated $128M.
  • OrbiMed's ten largest holdings make up 40% of its $6.46B portfolio in Q1 2019.
  • OrbiMed opened 25 new positions and closed 31 in Q1 2019.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.